Home » Stocks » TLSA

Tiziana Life Sciences PLC (TLSA)

Stock Price: $2.32 USD -0.10 (-4.13%)
Updated December 3, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 1.17M
Revenue (ttm) n/a
Net Income (ttm) -9.32M
Shares Out 136.46M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $2.32
Previous Close $2.42
Change ($) -0.10
Change (%) -4.13%
Day's Open 2.45
Day's Range 2.21 - 2.45
Day's Volume 359,068
52-Week Range 0.67 - 6.99

More Stats

Market Cap 1.17M
Enterprise Value 1.79M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 136.46M
Float n/a
EPS (basic) -0.14
EPS (diluted) -0.14
FCF / Share -0.10
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 490,868
Short Ratio 2.48
Short % of Float n/a
Beta 1.19
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 44.37
Revenue n/a
Operating Income -9.92M
Net Income -9.32M
Free Cash Flow -6.80M
Net Cash -620,000
Net Cash / Share -1.23
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -82.38%
ROE -804.99%
ROIC 217.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $2.32
Target: 4.35
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-9.92-9.87-10.49-9.88
Net Income-9.32-7.93-8.59-9.77
Shares Outstanding136141--
Earnings Per Share-0.14-0.12-0.18-0.22
Operating Cash Flow-6.80-4.60-7.53-6.93
Capital Expenditures----0.05
Free Cash Flow-6.80-4.60-7.53-6.97
Cash & Equivalents0.205.300.065.80
Total Debt0.82---
Net Cash / Debt-0.625.300.065.80
Book Value-5.510.52-2.284.09
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Tiziana Life Sciences PLC
Employees 8
CEO Shailubhai Kunwar

Stock Information

Ticker Symbol TLSA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TLSA
IPO Date March 24, 2000


Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.